Business
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
BASEL, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data. BV100 demonstrated a dose-proportional pharmacokinetic profile and was generally safe and well tolerated.BV100 global Phase 3 clinical trial is initiated with read-out expected in H2 2027.Additional Phase 2b to demonstrate clinical differentiation and further de-risk BV100’s registrational path to be initiated in 202
About this update from Bioversys Ag
[{"type":"image","alt":"BioVersys","displaySize":"","headline":null,"caption":"BioVersys","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Zo6ExiGAEwq5bzAtMXIVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47","width":300,"height":65}},"lazy":false},{"type":"text","content":"BASEL, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) --","length":54,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data. ","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"BV100 demonstrated a dose-proportional pharmacokinetic profile and was generally safe and well tolerated.","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"BV100 global Phase 3 clinical trial is initiated with read-out expected in H2 2027.","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional Phase 2b to demonstrate clinical differentiation and further de-risk BV100’s registrational path to be initiated in 2026 with interim data read-out expected end of 2026.","length":180,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":494,"olType":false},{"type":"text","content":"BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today, the publication of Phase 1, single- and multiple-ascending dose (SAD and MAD) clinical trial data including pharmacokinetics, safety and tolerability of BV100 in healthy volunteers in the Journal of Antimicrobial Agents and Chemotherapy.1","length":493,"tagName":"p"},{"type":"text","content":"BV100 is a novel intravenous formulation of rifabutin based on the newly identified mode of action for the active uptake of rifabutin into the Acinetobacter baumannii-calcoaceticus complex. BV100 is being developed for MDR hospital infections caused by Acinetobacter baumannii, including carbapenem-resistant strains.","length":317,"tagName":"p"},{"type":"t...